Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
Biol Pharm Bull ; 47(3): 692-697, 2024 Mar 25.
Article in English | MEDLINE | ID: mdl-38417893

ABSTRACT

Existing antiemetic therapy against emetic-risk agents across malignancies 24 h post-dose in the acute period in cisplatin (CDDP)-based regimens yields a satisfactory complete response (CR) rate of ≥90%. However, the control rate after 24 h in the delayed period is unsatisfactory. This study compared the efficacy of fosnetupitant (F-NTP), a neurokinin 1 receptor antagonist, with that of fosaprepitant (F-APR) and aprepitant (APR) in the treatment of patients with cancer at high emetic risk due to chemotherapy. In this retrospective case-control study involving patients receiving cisplatin-containing regimens and neurokinin 1 receptor antagonists, patients were divided into three groups based on prophylactic antiemetic therapy: F-NTP, F-APR, and APR. The CR rate was evaluated for each period up to 168 h and further subdivided into acute (0-24 h), delayed (24-120 h), overall (0-120 h), and beyond-delayed (120-168 h) periods. Eighty-eight patients were included in the F-NTP group, 66 in the F-APR group, and 268 in the APR group. The CR rates at 0-168 and 120-168 h after cisplatin administration were significantly higher in the F-NTP group than in the F-APR and APR groups. After adjusting for confounding factors, F-NTP use was an independent factor in the multivariate analysis. Prophylactic antiemetic therapy, including F-NTP, was effective and well-tolerated during the delayed period. The efficacy of F-NTP in managing chemotherapy-induced nausea and vomiting was superior to those of F-APR and APR during the study period.


Subject(s)
Antiemetics , Antineoplastic Agents , Morpholines , Neoplasms , Humans , Aprepitant/therapeutic use , Cisplatin/adverse effects , Emetics/adverse effects , Retrospective Studies , Case-Control Studies , Vomiting/chemically induced , Vomiting/prevention & control , Vomiting/drug therapy , Neurokinin-1 Receptor Antagonists/therapeutic use , Neurokinin-1 Receptor Antagonists/pharmacology , Neoplasms/drug therapy , Gastrointestinal Agents/therapeutic use , Antineoplastic Agents/adverse effects
2.
J Oncol Pharm Pract ; : 10781552231200427, 2023 Sep 12.
Article in English | MEDLINE | ID: mdl-37697894

ABSTRACT

INTRODUCTION: Kitasato University Hospital offers a training course for community pharmacists that focus on advanced pharmacy management care in outpatient cancer chemotherapy. The objective of this training program is to facilitate the transition from general to oncology certification for community pharmacists with limited experience in outpatient oncology to support the acquisition of an oncology specialty. AIM: To evaluate the relationship between the changes in awareness, knowledge, and self-assessment that advanced pharmacy management care traineeship in an outpatient oncology unit for community pharmacists brings to trainees and the duration of training. METHODS: A quantitative text analysis was conducted of the daily training reports of six community pharmacists who had participated previously in the training course and had received in-service training in oncology for at least 30 days. The pre- and post-training results of the knowledge tests and self-assessments of confidence, understanding, and performance were compared. This study was approved by the Research Ethics Committee of Kitasato Institute Hospital in October 2019 (Study No. 19044). RESULTS: The terms Prescription, Recommendation were extracted from the daily report after the 21st day of oncology in-service training. Furthermore, factors such as knowledge of cancer pharmacotherapy, confidence in patient education regarding the side effects of chemotherapy, and understanding of the work of pharmacists in outpatient cancer chemotherapy significantly increased at the end of the training. CONCLUSIONS: Community pharmacists with limited experience in outpatient oncology could improve their knowledge, understanding, and awareness of outpatient oncology patient care through 30 days of in-service oncology training in a hospital setting. The issues that emerged included training pharmacists to send follow-up documents on the patients' side effects and medication status as well as developing the literature search environment in community pharmacies.

3.
Article in English | MEDLINE | ID: mdl-28074152

ABSTRACT

BACKGROUND: Few studies have reported the dosage of cefmetazole (CMZ) for intraoperative antimicrobial prophylaxis in patients underwent surgery for colorectal cancer. We therefore examined the optimal intraoperative dosage of CMZ according to pharmacokinetic/pharmacodynamic (PK/PD) theory in patients who undergoing surgery for colorectal cancer. METHODS: The study group comprised 23 patients with colorectal cancer who underwent surgery, using CMZ as antimicrobial treatment to prevent postoperative infection. CMZ was administered intravenously within 60 min before surgery. PK/PD analysis was performed by population pharmacokinetic analysis and Monte-Carlo simulation. RESULTS: The final population pharmacokinetic parameters of CMZ were as follows: CLCMZ = 0.0704 × creatinine clearance (Ccr) and VdCMZ = 0.163 × body weight (Bw). In patients with a Ccr of ≥90 to <130 mL/min, the probability of achieving concentrations exceeding MIC was 52.9 to 82.2% at 2 h after the initial dose and less than 20% at 3 h after the initial dose. CONCLUSIONS: Additional doses of CMZ should be given every 2 h in patients with a Ccr of ≥90 to <130 mL/min, every 3 h in those with a Ccr of ≥50 to <90 mL/min, and every 4 to 5 h in those with a Ccr of ≥10 to <50 mL/min.

4.
Hepatogastroenterology ; 60(126): 1371-5, 2013 Sep.
Article in English | MEDLINE | ID: mdl-23933929

ABSTRACT

BACKGROUND/AIMS: This study was designed to clarify the pharmacokinetics of prophylactically administered cefmetazole in serum, intestinal tissue, and subcutaneous adipose tissue in patients who underwent surgery for colorectal cancer. METHODOLOGY: Cefmetazole sodium (1 g) was given intravenously during the induction of anesthesia, followed by a 1-g dose after 3 hours. Blood samples were taken at the start of surgery, immediately before administration of the additional dose of cefmetazole, at the time of lesion resection, and at the time of wound closure. Tissue samples were obtained immediately after lesion resection and at the time of wound closure. Concentrations of cefmetazole in serum and tissue were measured by high performance liquid chromatography using an internal standard for calibration. Minimum inhibitory concentrations (MIC80) of cefmetazole for Escherichia coli, Klebsiella pneumoniae, and Bacteroides fragilis were measured, and pharmacokinetics were evaluated. RESULTS: In subcutaneous adipose tissue, cefmetazole concentrations were maintained higher than the MIC80's for E. coli and K. pneumoniae, but were low in all patients regardless of the time of measurement. CONCLUSIONS: The low transition rate of cefmetazole into subcutaneous adipose tissue indicates the need for additional measures, such as high-pressure washing of the subcutaneous wound tissue.


Subject(s)
Anti-Bacterial Agents/pharmacokinetics , Antibiotic Prophylaxis , Cefmetazole/pharmacokinetics , Colorectal Neoplasms/surgery , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Subcutaneous Fat/metabolism , Tissue Distribution
5.
Radiat Res ; 172(4): 519-24, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19772473

ABSTRACT

The effects of TMG [2-(alpha-d-glucopyranosyl) methyl-2,5,7,8-tetramethylchroman-6-ol], a water-soluble vitamin E derivative, administered after irradiation on the mortality of X-irradiated mice and on the development of tumors in the mammary and pituitary glands in rats were investigated. When TMG (650 mg/kg) was administered intraperitoneally (i.p.) to C3H mice immediately after whole-body exposure to 7 Gy radiation, the 30-day survival was significantly higher than that of the control mice. The i.p. administration of TMG at 4 h after irradiation significantly improved survival compared to that of the controls, but administration 8 h after irradiation did not have a significant effect. Subcutaneous administration of TMG immediately after irradiation also decreased mortality significantly. When dams of lactating Wister rats were exposed to 1.5 Gy of X rays at day 21 after parturition and were then treated with diethylstilbestrol as a tumor promoter, the incidence of mammary tumors and pituitary tumors was increased compared to that in the nonirradiated control group. The administration of TMG (600 mg/kg, i.p.) after irradiation significantly reduced the incidence of mammary tumors and pituitary tumors. The number of rats that were free of both mammary and pituitary gland tumors was enhanced fourfold by TMG. These results suggest that TMG is effective in preventing radiation-induced bone marrow death in mice and in reducing mammary and pituitary tumors in rats even when it is administered after irradiation.


Subject(s)
Free Radical Scavengers/administration & dosage , Free Radical Scavengers/pharmacology , Glucosides/administration & dosage , Glucosides/pharmacology , Neoplasms, Radiation-Induced/pathology , Neoplasms, Radiation-Induced/prevention & control , Animals , Bone Marrow/drug effects , Bone Marrow/radiation effects , Breast Neoplasms/pathology , Breast Neoplasms/prevention & control , Mice , Mortality , Pituitary Neoplasms/pathology , Pituitary Neoplasms/prevention & control , Rats , Time Factors , Tocopherols/administration & dosage , Tocopherols/pharmacology , X-Rays/adverse effects
6.
Nitric Oxide ; 12(1): 15-20, 2005 Feb.
Article in English | MEDLINE | ID: mdl-15631943

ABSTRACT

This study evaluated whether nitric oxide (NO) derived from nitric oxide synthase (NOS) induced by radiation is associated with tumorigenesis in the mammary glands. When rats were exposed to whole-body irradiation with gamma-rays (1.5 Gy) immediately after weaning and then treated with diethylstilbestrol, as an irradiated control, the tumor incidence (85%) was increased 7.6-fold in comparison with that (11.1%) of the non-irradiated control. The tumor incidence declined to 28.6% in the rats injected intraperitoneally with phenyl-N-tert-butylnitrone (PBN, 160 mg/kg), an inhibitor of inducible NOS (iNOS) expression and also a spin trapping agent, 30 min before irradiation. Also, the tumor incidence (25%) in rats orally administered with N-(3-(aminomethyl)-benzyl)-acetamide (1400W, 2.3+/-0.1 mg/day), a highly selective inhibitor of iNOS, dissolved in drinking water for 3 days after the irradiation was less than one-third of that in the irradiated control. On treatment with PBN or 1400W, no adenocarcinoma developed. Many of the mammary tumors that developed in the irradiated rats were positive for the estrogen receptor (ER). In contrast, ER was not detected in the tumors yielded from irradiated rats administered with PBN or 1400W. These results indicate that iNOS-derived NO may participate in the formation of estrogen-dependent mammary adenocarcinomas following radiation.


Subject(s)
Adenocarcinoma/prevention & control , Mammary Glands, Animal/radiation effects , Mammary Neoplasms, Experimental/prevention & control , Neoplasms, Radiation-Induced/prevention & control , Nitric Oxide Synthase/metabolism , Nitric Oxide/biosynthesis , Adenocarcinoma/chemically induced , Adenocarcinoma/pathology , Amidines/pharmacology , Animals , Benzylamines/pharmacology , Carcinogens , Diethylstilbestrol , Dose-Response Relationship, Radiation , Enzyme Inhibitors/pharmacology , Evaluation Studies as Topic , Female , Mammary Glands, Animal/drug effects , Mammary Glands, Animal/metabolism , Mammary Neoplasms, Experimental/chemically induced , Mammary Neoplasms, Experimental/pathology , Neoplasms, Radiation-Induced/chemically induced , Neoplasms, Radiation-Induced/pathology , Nitric Oxide Synthase/antagonists & inhibitors , Nitric Oxide Synthase Type II , Nitrobenzenes , Nitrogen Oxides/pharmacology , Pregnancy , Rats , Rats, Wistar , Receptors, Estrogen/drug effects , Receptors, Progesterone/drug effects , Whole-Body Irradiation
7.
Nitric Oxide ; 8(2): 144-8, 2003 Mar.
Article in English | MEDLINE | ID: mdl-12620378

ABSTRACT

Nitric oxide (NO) and its reaction products have been shown to cause DNA damage and to be mutagenic. To elucidate whether NO produced by irradiation participates in the initiation of mammary tumorigenesis, we performed experiments using the nitric oxide-specific scavenger Fe(2+)-diethyldithiocarbamate complex (Fe(DETC)(2)) or a selective inhibitor for inducible nitric oxide synthase (iNOS), S,S(')-(4-phenylene-bis(1,2-ethanedinyl))bis-isothiourea (1,4-PB-ITU). Mother rats at day 21 of lactation were injected simultaneously with diethyldithiocarbamate intraperitoneally and Fe(2+)-citrate subcutaneously to form Fe(DETC)(2), in vivo, and then irradiated with 1.5Gy gamma-rays immediately after the injection. An additional injection of chemicals followed twice at 8 and 24h after the irradiation in the same manner. Both control and treated rats were then implanted with diethylstilbestrol pellets as a tumor promoter. The mammary tumor incidence in the experimental group was significantly reduced to one-fourth of that in the irradiated-alone group as the control. On the other hand, when mother rats took drinking water containing 0.005% 1,4-PB-ITU for 6 days from 3 days prior to irradiation at day 21 of lactation, a low tumor incidence in the iNOS inhibitor-treated groups was observed in the 1-year period. This report is the first to show that the NO derived from iNOS is an important radical for radiation-induced initiation of tumorigenesis of mammary glands in rats.


Subject(s)
Mammary Neoplasms, Experimental/etiology , Neoplasms, Radiation-Induced/etiology , Nitric Oxide/metabolism , Animals , Enzyme Inhibitors/pharmacology , Female , Ferrous Compounds/pharmacology , Free Radical Scavengers/pharmacology , Lactation , Mammary Neoplasms, Experimental/prevention & control , Neoplasms, Radiation-Induced/prevention & control , Nitric Oxide/pharmacology , Nitric Oxide Synthase/antagonists & inhibitors , Nitric Oxide Synthase/biosynthesis , Nitric Oxide Synthase Type II , Rats , Rats, Wistar
8.
Int J Radiat Oncol Biol Phys ; 53(3): 735-43, 2002 Jul 01.
Article in English | MEDLINE | ID: mdl-12062620

ABSTRACT

PURPOSE: We evaluated the radioprotective action of curcumin [1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione] extracted from Curcuma longa LINN against the acute and chronic effects and the mortality induced by exposure to radiation using female rats. METHODS AND MATERIALS: For the assay of 8-hydroxy-2'-deoxyguanosine (8-OHdG) in urine, a marker for acute effects, Wistar-MS virgin rats were fed the basal diet with exposure at 0 or 3 Gy to gamma-rays from a 60Co source as the control. Rats in the experimental groups received whole-body irradiation with 3 Gy and were fed a diet containing 1% (wt/wt) curcumin for 3 days before and/or 2 days after irradiation. The urine was collected for a 24-h period between 1 and 2 days after irradiation. Urine samples were used to determine the 8-OHdG level using an enzyme-linked immunosorbent assay and the creatinine level by a modified Jaffé reaction. For long-term effects, rats at Day 17 of pregnancy were fed a diet containing curcumin for 3 days before and/or 3 days after irradiation with 1.5 Gy, and received a pellet of diethylstilbestrol as the promoter. The rats were examined for mammary and pituitary tumors for 1 year. To determine survival, virgin rats received whole-body irradiation with 9.6 Gy and were fed a diet containing curcumin for 3 days before and/or 3 days after irradiation. After irradiation, all rats were assessed daily for survival for 30 days. RESULTS: Acutely in virgin rats irradiated with 3 Gy, the creatinine-corrected concentration and total amount of 8-OHdG in the 24-h urine samples were higher (approximately 1.3-fold) than the corresponding values in the nonirradiated controls. Adding curcumin to the diet for 3 days before and/or 2 days after irradiation reduced the elevated 8-OHdG levels by 50-70%. The evaluation of the protective action of curcumin against the long-term effects revealed that curcumin significantly decreased the incidence of mammary and pituitary tumors. However, the experiments on survival revealed that curcumin was not effective when administered for 3 days before and/or 3 days after irradiation (9.6 Gy). CONCLUSION: These findings demonstrate that curcumin can be used as an effective radioprotective agent to inhibit acute and chronic effects, but not mortality, after irradiation.


Subject(s)
Curcumin/pharmacology , Deoxyguanosine/analogs & derivatives , Deoxyguanosine/urine , Mammary Neoplasms, Experimental/prevention & control , Neoplasms, Radiation-Induced/prevention & control , Pituitary Neoplasms/prevention & control , Radiation-Protective Agents/pharmacology , 8-Hydroxy-2'-Deoxyguanosine , Acute Disease , Animals , Biomarkers/urine , Carcinogens , Creatinine/urine , Diethylstilbestrol , Drug Evaluation, Preclinical , Female , Mammary Neoplasms, Experimental/mortality , Mammary Neoplasms, Experimental/urine , Neoplasms, Radiation-Induced/mortality , Neoplasms, Radiation-Induced/urine , Pituitary Neoplasms/mortality , Pituitary Neoplasms/urine , Pregnancy , Rats , Rats, Wistar , Whole-Body Irradiation/mortality
9.
Int J Radiat Oncol Biol Phys ; 52(1): 212-23, 2002 Jan 01.
Article in English | MEDLINE | ID: mdl-11777641

ABSTRACT

The radiation-induced rat mammary tumor model is useful for studying tumor prevention by treatment in the initiation or promotion stage. In anti-initiation experiments, the administration of radical scavengers or spin-trapping agents before or immediately after irradiation reduced the incidence of mammary tumors, suggesting that free radicals produced by exposure are a potent initiator. To evaluate the role of nitric oxide (NO) in the initiation, NO-specific scavengers or NO synthase inhibitors were administered during the initiation. These agents partially prevented the tumorigenesis, suggesting that radiation-induced NO contributes to tumor initiation. The administration of curcumin during irradiation reduced the incidence of the tumors in the presence of tumor promotor. In anti-promotion experiments on preventing diethylstilbestrol (DES)-dependent tumor development from mammary primodial cells exposed to radiation, tamoxifen decreased the tumor incidence. From the results, estrogen itself or prolactin induced by estrogen may be a promoter for the tumorigenesis. Bezafibrate and simvastatin, agents inducing hypolipidemia and hypocholesterolemia respectively, cause a decrease in the DES-dependent promotion of radiation-induced tumorigenesis. The simultaneous administration of curcumin and DES significantly reduces the development of mammary tumors in irradiated rats. In this review, the endocrinologic and pharmacologic significance of the anti-initiation and anti-promotion is discussed.


Subject(s)
Mammary Neoplasms, Experimental/prevention & control , Neoplasms, Radiation-Induced/prevention & control , Anticarcinogenic Agents/pharmacology , Antineoplastic Agents/pharmacology , Carcinogens , Curcumin/pharmacology , Cyclic N-Oxides , Diethylstilbestrol , Energy Intake , Enzyme Inhibitors/pharmacology , Female , Free Radical Scavengers/pharmacology , Humans , Nitric Oxide/chemistry , Nitric Oxide Synthase/antagonists & inhibitors , Nitrogen Oxides/pharmacology , Ovariectomy , Radiation-Protective Agents/pharmacology , Spin Trapping
SELECTION OF CITATIONS
SEARCH DETAIL
...